Valeant Chairman Robert O’Leary
Executive Summary
Valeant Chairman Robert O'Leary died at the age of 62 following a long battle with cancer, company announces Aug. 14. Board elects GlaxoSmithKline Vice Chairman-Pharmaceuticals Robert Ingram, a member of Valeant's board since 2003, to serve as chairman. Ingram has also chaired OSI Pharmaceutical's board since 2003 (1"The Pink Sheet" Jan. 13, 2003, In Brief)...
You may also be interested in...
OSI hires GSK’s Ingram
GlaxoSmithKline Vice Chairman-Pharmaceuticals Robert Ingram joins OSI Pharmaceuticals as chairman of board of directors in a non-executive capacity, effective Jan. 1. "Ingram will assume chairmanship of the Board's executive, nominating and compensation committees," OSI said. OSI CEO Colin Goddard relinquishes chairmanship of board. Ingram retired as GSK chief operating officer and pharmaceutical operations president in December (1"The Pink Sheet" Oct. 21, 2002, p. 27)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.